

PATENT APPLICATION

ATTORNEY DOCKET 27129/33783B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: White et al.

Serial No: 09/994,185

Filed: November 26, 2001

For: "Method for Quantifying LBP in Body Fluids"

Group Art Unit: TBD

Examiner: TBD

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, postage prepaid in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this date:

February 25, 2002

[Signature]

P#5

Jeffrey S. Sharp
Registration No. 31,879
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT WITH PTO-1449 FORM

**Commissioner for Patents
Washington, DC 20231**

Sir:

In compliance with 37 C.F.R. §1.97 and the duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by the Applicants for consideration in connection with the above-identified patent application. Pursuant to 37 C.F.R. §1.98(d), copies of the documents cited on the PTO-1449 form are not being provided because they were previously cited by or submitted to the Patent Office in grandparent application U.S. Serial No. 08/779,400 or great grandparent application U.S. Serial No. 08/377,391, from which priority is claimed under 35 U.S.C. §120. Should the Examiner desire additional copies of the documents, Applicants will provide them upon request.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This Information Disclosure Statement is submitted within three months of the filing date and before the receipt of an Office Action on the merits of the above-identified

application and consequently should be considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855. A copy of this paper is enclosed herewith.


MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By


Jeffrey S. Sharp
Registration No.: 31,879
Attorney for Applicants

February 25, 2002

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27129/33783BSerial No.
09/994,185**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,484,705	01/16/96	White			
	A2	5,245,013	09/14/93	Ulevitch			
	A3	5,310,879	05/10/94	Ulevitch			

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 91/01639	02/21/91	PCT				
	B2	WO 93/06228	04/01/93	PCT				
	B3	WO 94/21280	09/29/94	PCT				
	B4	WO 94/25476	11/10/94	PCT				
	B5	WO 95/00641	01/05/95	PCT				
	B6	WO 95/02414	01/26/95	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27129/33783BSerial No.
09/994,185**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Dofferhoff <i>et al.</i> , "Tumor necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature", <i>Netherlands J. Med.</i> , 39:45-62 (1991).
C2	Elsbach <i>et al.</i> , "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A ₂ from Rabbit Polymorphonuclear Leukocytes", <i>J. Biol. Chem.</i> , 254(21):11000-11009 (November 10, 1979).
C3	Erwin and Munford, "Plasma Lipopolysaccharide-Deacylating Activity (Acyloxyacyl Hydrolase) Increases After Lipopolysaccharide Administration to Rabbits", <i>Lab. Invest.</i> , 65(2):138-144 (1991).
C4	Gallay <i>et al.</i> , "Purification and Characterization of Murine Lipopolysaccharide-Binding Protein", <i>Infect. Immun.</i> 61(2):378-383 (February 1993).
C5	Gazzano-Santoro <i>et al.</i> , "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", <i>Infect. Immun.</i> 60(11):4754-4761 (November 1992).
C6	Leturcq <i>et al.</i> , "Generation of Monoclonal Antibodies to Human LBP and Their Use in the Detection of LBP Protein in Serum", <i>J. Cell. Biochem.</i> , 16C:161 (1992).
C7	Marra <i>et al.</i> , "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", <i>J. Immun.</i> , 148(2):532-537 (January 15, 1992).
C8	Pereira <i>et al.</i> , "Quantitation of a cationic antimicrobial granule protein of human polymorphonuclear leukocytes by ELISA", <i>J. Immunol. Methods</i> , 117:115-120 (1989).
C9	Pesce <i>et al.</i> , "Cationic antigens Problems associated with measurement by ELISA", <i>J. Immunol. Methods</i> , 87:21-27 (1986).
C10	Schindler <i>et al.</i> , "Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis", <i>Clin. Nephrology</i> , 40(6):346-351 (1993).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 27129/33783B	Serial No. 09/994,185
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant White <i>et al.</i>		
		Filing Date November 26, 2001	Group TBD	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C11	Schumann <i>et al.</i> , "Structure and Function of Lipopolysaccharide Binding Protein", <i>Science</i> , 249:1429-1433 (September 21, 1990).
C12	Spitznugel, "Antibiotic Proteins of Human Neutrophilia", <i>J. Clin. Invest.</i> , 86:1381-1386 (1990).
C13	Taber <i>et al.</i> , Taber's Cyclopedic Medical Dictionary, pp 545 (F.A. Davis Co., Philadelphia) (1985).
C14	Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993).
C15	von der Mohien <i>et al.</i> , Bactericidal/Permeability-Increasing Protein Levels Predict Survival in Patients with Gram-Negative Sepsis", Abstract presented at 13th International Symposium on Intensive Care and Emergency Medicine, (Brussels, Belgium) (March 1993).
C16	Weiss and Olsson, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", <i>Blood</i> , 69(2):652-659 (February 1987).
C17	Weiss <i>et al.</i> , "Human Bactericidal/Permeability-Increasing Protein and a Recombinant NH ₂ - Terminal Fragment Cause Killing of Serum-resistant Gram-negative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria", " <i>J. Clin. Invest.</i> 90:1122-1130 (September 1992).
C18	Weiss <i>et al.</i> , "Purification and Characterization of a Potent Bactericidal and Membrane Active Protein from the Granules of Human Polymorphonuclear Leukocytes", <i>J. Biol. Chem.</i> , 253(8):2664-2672 (April 25, 1978).
C19	White <i>et al.</i> , "Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA", <i>J. Immunol. Methods</i> , 167:227-235 (1994).
C20	Wright <i>et al.</i> , "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein", <i>Science</i> , 249:1431-1433 (September 21, 1990).
C21	Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993) (Session 13 Abstract 564).

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27129/33783BSerial No.
09/994,185

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


C22	Tobias et al., "Lipopolysaccharide Binding Protein" <i>J. Cell. Biochem.</i> , 16 C:151 (Abstract (CB006) (1992)
C23	Ballou et al., "Laboratory Evaluation of Inflammation," <i>Textbook of Rheumatology</i> , Vol. 1, Ch. 40, pp. 671-679 (1993)
C24	Baumann et al., "The acute phase response," <i>Immunology Today</i> , Vol. 15, 1/4 1/2 . 2, pp. 74-80 (1994)
C25	Grube et al., "Lipopolysaccharide Binding Protein Expression in Primary Human Hepatocytes and HepG2 Hepatoma Cells*", <i>J. Biol. Chem.</i> , Vol. 269, No. 11, pp. 8477-8482 (1994)
C26	Raynes, "Carbohydrate Binding Proteins and Immune Responses," Biochemical Immunology Group/Glycobiology Group Joint Colloquium Organized by G.B. Wisdom and M.I. Halliday (The Queen's University, Belfast) and Edited by G.B. Wisdom. 648th Meeting held at the Queen's University, Belfast, 14-17 September 1993, <i>Biochemical Society Transactions</i> , Vol. 22, pp. 69-74 (1994)
C27	Meszaros et al., "Immunoreactivity and Bioactivity of Lipopolysaccharide-Binding Protein in Normal and Heat-Inactivated Sera," <i>Infection and Immunity</i> , Vol. 63, No. 1, pp. 363-366 (1995)
C28	Pugin et al., "Soluble CD14 and Lipopolysaccharide Binding Protein Mediate Epithelial Cell Responses to Lipopolysaccharides," <i>FASEB J.</i> , A142 (1993)
C29	Geller et al., <i>Arch. Surg.</i> , 128:22-28 (1993)
C30	Tobias, <i>J. Biol. Chem.</i> , 263:13479-13481 (1988)
C31	Schumann, <i>Science</i> , 249:1429-1431 (1990)
C32	Dubin et al., "Asthma and Endotoxin: Lipopolysaccharide-Binding Protein and Soluble CD14 in Bronchoalveolar Compartment," <i>Am. J. Physiol.</i> , 270:L736-L744 (1996)
C33	Froon et al., "Lipopolysaccharide Toxicity -- Regulating Proteins in Bacteremia," <i>J. Infect. Dis.</i> , 171:1250-1257 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27129/33783BSerial No.
09/994,185**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant
*White et al.*Filing Date
November 26, 2001Group
TBD**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

C34	Heumann et al., "Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma," <i>J. Immunol. Meth.</i> , 171:169-176 (1994)
C35	Iriye et al., "Differences in the Concentration of an Endotoxin Binding Protein Help Explain Sensitivity to Septic Complications in Pregnancy," <i>Am. J. Obstetrics Gynecol.</i> , 174(pt. 2):390 (1996)
C36	Nakayama et al., "Monitoring Both Serum Amyloid Protein A and C-Reactive Proteins as Inflammatory Markers in Infectious Diseases," <i>Clin. Chem.</i> 39:293-297 (1993)
C37	Schumann et al., 36th Int'l Conf. on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, (1996)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.